Herui Yao
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Second Affiliated Hospital, Sun Yat-Sen University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Herui Yao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:58 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07601334 · Safety and Activity of HF50 in Patients With Advanced Solid TumorsHighField Biopharmaceuticals Corporation · recruiting · Advanced Solid Tumors · principal investigator
- N/ANCT07504367 · Large Language Models Assist in Tumor MDTSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · recruiting · Lung Cancer, Breast Cancer, Colorectal Cancer · study director
- N/ANCT06510127 · An AI Model Predicts the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Bidirectional Cohort StudySun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Breast Cancer · study director
- Ph2NCT06445400 · A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · HER2-positive Breast Cancer · principal investigator
- Ph1/Ph2NCT06431243 · A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid TumorsChengdu Zenitar Biomedical Technology Co., Ltd · recruiting · Advanced Solid Tumor · principal investigator
- Ph3NCT06316531 · A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · HER2-positive Breast Cancer · principal investigator
- Ph2NCT05895864 · Utidelone Treated for the Recurrent or Metastatic Urothelial CarcinomaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Metastatic Urothelial Carcinoma · principal investigator
- Ph1NCT05461768 · A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Breast Cancer, Locally Advanced or Metastatic Solid Tumor · principal investigator
- Ph1NCT05339685 · A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT05068141 · A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · unknown · Triple Negative Breast Cancer · study chair
- Ph1NCT04993040 · A PK Study of Oraxol in Breast Cancer PatientsAthenex, Inc. · completed · Breastcancer · principal investigator
- N/ANCT04551287 · Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical CancerSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · completed · Cervical Cancer, Diagnostic Platform, Diagnosing Cervical Cytology Grades and Cancer · principal investigator
- N/ANCT04456855 · Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer PatientsSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Breast Neoplasm Female, Surgery, Advanced Breast Cancer · study chair
- N/ANCT04452058 · CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLCSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Predictive Cancer Model, Lung Cancer, Preinvasive Adenocarcinoma · study director
- Ph3NCT04263298 · Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerHerui Yao · recruiting · Metastatic Breast Cancer · study chair
- N/ANCT04258163 · Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line ChemotherapySun Yat-Sen Memorial Hospital of Sun Yat-Sen University · completed · Metastatic Breast Cancer · study chair
- Ph1NCT04060511 · A Study of HS-10342 in Patients With Advanced Solid TumorJiangsu Hansoh Pharmaceutical Co., Ltd. · completed · Advanced Solid Tumor · principal investigator
- N/ANCT04027543 · Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · completed · Radiotherapy Side Effect, Chemotherapy Effect, Oesophageal Carcinoma · study chair
- N/ANCT04004559 · MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Invasive Breast Cancer, Neoadjuvant Chemotherapy, Radiomics · study chair
- N/ANCT04003558 · Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Breast Neoplasm Female, Early-stage Breast Cancer, Radiomics · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:58 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- 240 citationsRCR 15.8
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.J Immunother Cancer · 2020154 citationsRCR 5.6
- 96 citationsRCR 5.7
- First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.Clin Cancer Res · 202269 citationsRCR 4.2
- 50 citationsRCR 5.0
- 13 citationsRCR 2.8
- Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.Cancer Commun (Lond) · 202513 citationsRCR 2.2
- SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.Signal Transduct Target Ther · 20265 citationsRCR 2.5
- Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.Cancer Chemother Pharmacol · 20211 citationsRCR 0.1
- A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer.J Cancer Res Clin Oncol · 20251 citationsRCR 0.5